Company profile for Oxford Biomedica

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Oxford BioMedica (OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. We have built a sector-leading lentiviral vector delivery platform, called LentiVector®, which we use to develop in vivo and ex vivo products both in-house and with partners. We have created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, op...
Oxford BioMedica (OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. We have built a sector-leading lentiviral vector delivery platform, called LentiVector®, which we use to develop in vivo and ex vivo products both in-house and with partners. We have created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. We also have a number of partnerships, including with Novartis, Sanofi, GSK and Orchard Therapeutics, where we have long-term economic interests in other potential gene and cell therapy

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
Windrush Court Transport Way Oxford OX4 6LT
Telephone
Telephone
+44 (0) 1865 783 000
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercepharma.com/manufacturing/cdmo-oxb-raises-ps60m-share-placing-support-us-expansion-ambitions

FIERCE PHARMA
18 Aug 2025

https://www.globenewswire.com/news-release/2025/06/23/3103252/0/en/OXB-completes-acquisition-of-remaining-stake-in-US-subsidiary.html

GLOBENEWSWIRE
23 Jun 2025

https://www.globenewswire.com/news-release/2024/09/18/2948064/0/en/Oxford-Biomedica-rebrands-as-OXB-reinforcing-transformation-into-leading-global-cell-and-gene-therapy-CDMO.html

GLOBENEWSWIRE
18 Sep 2024
Oxford Biomedica Rebrands as OXB
Oxford Biomedica Rebrands as OXB

18 Sep 2024

// CONTRACT PHARMA

https://www.contractpharma.com//contents/view_breaking-news/2024-09-18/oxford-biomedica-rebrands-as-oxb/?widget=listSection

CONTRACT PHARMA
18 Sep 2024

https://www.globenewswire.com/news-release/2024/09/02/2939007/0/en/Lucinda-Crabtree-joins-Oxford-Biomedica-as-Chief-Financial-Officer-today.html

GLOBENEWSWIRE
02 Sep 2024

https://www.globenewswire.com/news-release/2024/08/27/2936105/0/en/Oxford-Biomedica-to-host-a-free-webinar-showcasing-its-AAV-expertise.html

GLOBENEWSWIRE
27 Aug 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty